Effective delivery of large genes to the retina by dual AAV vectors
Open accessThe DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.
Abstract
Retinal gene therapy with adeno‐associated viral (AAV) vectors is safe and effective in humans. However, AAV's limited cargo capacity prevents its application to therapies of inherited retinal diseases due to mutations of genes over 5 kb, like Stargardt's disease (STGD) and Usher syndrome type IB (USH1B). Previous methods based on ‘forced’ packaging of large genes into AAV capsids may not be easily translated to the clinic due to the generation of genomes of heterogeneous size which raise safety concerns. Taking advantage of AAV's ability to concatemerize, we generated dual AAV vectors which reconstitute a large gene by either splicing (trans‐splicing), homologous recombination (overlapping), or a combination of the two (hybrid). We found that dual trans‐splicing and hybrid vectors transduce efficiently mouse and pig photoreceptors to levels that, albeit lower than those achieved with a single AAV, resulted in significant improvement of the retinal phenotype of mouse models of STGD and USH1B. Thus, dual AAV trans‐splicing or hybrid vectors are an attractive strategy for gene therapy of retinal diseases that require delivery of large genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Even though vector reconstitution in the retina has been detected for clinically relevant large transgenes, such as ABCA4 or MYO7A, due to lack of proper controls (e.g., using oversized monocistronic vectors) and accurate protein quantification methods, determining parameters for clinical approaches has been lacking (Dyka et al., 2014; Trapani et al., 2014, 2015).”
From Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting (2017) · cites this paper as Trapani et al., 2014
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it is worth remembering that the multiplicity of infection is about 10 4 - 10 5 vector particles at the level of the RPE, depending on the disease state at the time of treatment (Trapani et al., 2014; Ramachandran et al., 2017).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Trapani et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“advances in dual and triple AAV vectors with enhanced cargo capacity now allow for the delivery of larger genes [242], including anti-VEGF and complement regulatory molecules”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [242]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The hybrid dual AAV strategy was initially proposed by Gosh and colleagues in 2008 [54] and found to significantly improve transgene reassembly in a variety of studies thereafter [29,49].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In their study, Trapani et al. demonstrated that in vitro transduction with vectors with oversized genomes did not result in efficient transgene expression. 46”
From Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids (2016) · cites this paper as [46]
Experimental — accuracy not yet measured
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statistics and Computing · doi:10.1007/978-0-387-21706-2 · Cited by 24,305 · cited 1×
“…lipo-fuscin granules (Fig 5D) are expressed as discrete numbers, these were analyzed by deviance from a Negative Binomial generalized linear models (Venables & Ripley, 2002) WT versus Abca4 (cid:1) / (cid:1) neg P = 0.016; WT versus Abca4 (cid:1) / (cid:1) AK-ABCA4 P = 0.03; Abca4 (cid:1) /…”
InfluentialThe Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
A monomeric red fluorescent protein
Campbell, R. E., Tour, O., Palmer, A. E., Steinbach, P. A., Baird, G. S., Zacharias, D. A., & Tsien, R. Y. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082243699 · Cited by 2,365 · cited 1×
“The membrane was then analyzed by X-ray autoradiography using Amersham Hyperfilm TM MP (GE Healthcare Europe, GmbH).”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 2×
“…gene therapy is effective in animal models and in patients with inherited blinding conditions (Jacobson et al , 2006; Bainbridge et al , 2008; Maguire et al , 2008, 2009; Cideciyan et al , 2009; Simonelli et al , 2010), its application to diseases affecting the retina and requiring a…”
Self-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“While AAV-mediated gene therapy is effective in animal models and in patients with inherited blinding conditions (Jacobson et al , 2006; Bainbridge et al , 2008; Maguire et al , 2008, 2009; Cideciyan et al , 2009; Simonelli et al , 2010), its application to diseases affecting the retina and…”
Allikmets, R., Singh, N., Sun, H., Shroyer, N. F., Hutchinson, A., Chidambaram, A., Gerrard, B., Baird, L., Stauffer, D., Peiffer, A., et al. (1997) · Nature Genetics · doi:10.1038/ng0397-236 · Cited by 1,435
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029 · cited 4×
“Although the Abca4 (cid:1) / (cid:1) mouse model does not undergo severe PR degeneration (Wu et al , 2010a), the absence of the ABCA4-encoded all-trans retinal transporter in PR outer segments (Illing et al , 1997; Sun & Nathans, 1997) causes an accumulation of lipo-fuscin in PR as well as in RPE,…”
InfluentialWeng, J., Mata, N. L., Azarian, S. M., Tzekov, R. T., Birch, D. G., & Travis, G. H. (1999) · Cell · doi:10.1016/s0092-8674(00)80602-9 · Cited by 881 · cited 5×
“ABCA4 and MYO7A expression was normalized to Filamin A or Dysferlin for the in vitro and in vivo experiments, respectively.”
InfluentialMaguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 2×
“…gene therapy is effective in animal models and in patients with inherited blinding conditions (Jacobson et al , 2006; Bainbridge et al , 2008; Maguire et al , 2008, 2009; Cideciyan et al , 2009; Simonelli et al , 2010), its application to diseases affecting the retina and requiring a…”
Self-citation
Cited by
Items 201–284 of 284
Next generation sequencing in the diagnosis of Stargardt's disease
Jimenez‐Rolando, B., Noval, S., Rosa-Pérez, I., Diaz, E. M., del Pozo, Á., Ibáñez, C., Silla-Castro, J. C., Montaño, V. E. F., Martín‐Arenas, R., & Vallespín, E. (2017) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2017.06.004 · Cited by 5
Targeting Age-Related Neurodegenerative Diseases by AAV-Mediated Gene Therapy
Cagin, U. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_15 · Cited by 5
Viral Vector Technologies and Strategies: Improving on Nature
Croze, R. H., Kotterman, M. A., Burns, C. H., Schmitt, C. E., Quezada, M., Schaffer, D. V., Kirn, D. H., & Francis, P. J. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000361 · Cited by 5
Gene Therapy for Inherited Retinopathies: Update on Development Progress
Sun, S. Y., & Montezuma, S. R. (2018) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126418783934 · Cited by 6
“Thus, AAV cannot be used as a vector for larger coding sequences unless it is modified to a dual AAV vector, which is in the preclinical stage of investigation.(11,12) Another vector used in gene therapy clinical trials for inherited retinopathies is lentivirus, which is able to carry 8 kb of DNA sequence.”
BackgroundSauter, M. M., & Brandt, C. R. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108436 · Cited by 5
Liu, F., Li, Q., Su, J., Fu, J., Wu, X., Xu, Q., Ren, C., Jin, X., Song, L., Lu, F., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.12.29 · Cited by 4
Recent advances towards BACE1 drug discovery and therapeutics design
Imran, S., Patel, M., Noroozifar, M., & Kerman, K. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md01095k · Cited by 5
Usher syndrome: Genetic diagnosis and current therapeutic approaches
Cuzzuol, B. R., Apolonio, J. S., Júnior, R. T. D. S., de Carvalho, L. S., Santos, L. K. D. S., Malheiro, L. H., Luz, M. S., Calmon, M. S., Crivellaro, H. D. L., Lemos, F. F. B., et al. (2024) · World Journal of Otorhinolaryngology · doi:10.5319/wjo.v11.i1.1 · Cited by 4
Gene therapy for inherited retinal diseases
Dhooge, P. P. A., Valkenburg, D., & Hoyng, C. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816222-4.00017-4 · Cited by 5
Challenges to Gene Editing Approaches in the Retina
Bonillo, M., Pfromm, J. K., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1757-9810 · Cited by 6
“[35] Trapani I, Colella P, Sommella A et al.”
BackgroundDu, C., Cotham, V. C., Thakur, G., Mink, S. R., Tustian, A. D., Møller-Tank, S., Wang, S., & Li, N. (2025) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.5c00206 · Cited by 3
Xun, M., Fan, X., Wang, H., Zhao, J., Tang, G., Zhang, W., Hu, S., Zhang, L., Wang, D., Chen, Y., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.002 · Cited by 3
Sauter, M. M., Noel, H., & Brandt, C. R. (2023) · Experimental Eye Research · doi:10.1016/j.exer.2023.109647 · Cited by 3
Gene Therapy for Blinding Pediatric Eye Disorders
Dumitrescu, A. V., & Drack, A. V. (2015) · Advances in Pediatrics · doi:10.1016/j.yapd.2015.04.012 · Cited by 3
Gene therapy for Leber congenital amaurosis
Kumaran, N., Smith, A. J., Michaelides, M., Ali, R. R., & Bainbridge, J. W. (2018) · Expert Review of Ophthalmology · doi:10.1080/17469899.2018.1429916 · Cited by 4
“component parts by multiple AAV vectors is reconstituted by splicing [13].”
BackgroundGene Therapy for Dominantly Inherited Retinal Degeneration
Farrar, G. J., Millington‐Ward, S., Palfi, A., Chadderton, N., & Kenna, P. F. (2014) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-662-45188-5_4 · Cited by 4
Self-citationAl‐Moyed, H. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7430 · Cited by 3
Key challenges in developing a gene therapy for Usher syndrome: machine-assisted scoping review
Bhat, R. S., Bhargavi, N., Shethia, F., CHHAYA, V. A., & KHAMBHOLJA, K. M. (2024) · Journal of Community Genetics · doi:10.1007/s12687-024-00749-0 · Cited by 2
Li, B., Zhao, C., Guo, S., Li, X., Zhang, H., Duan, Y., Zhang, M., Tao, Q., Zhou, P., Li, X., et al. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110273 · Cited by 2
Gene Therapy for Wet Age-Related Macular Degeneration
Barthelemy, N., Sridhar, J. S., & Sengillo, J. D. (2025) · Bioengineering · doi:10.3390/bioengineering12101072 · Cited by 6
“Since then, the sustained clinical improvements and favorable immunological profile of this therapy have inspired advances in vector design and driven clinical trials for Stargardt disease, choroideremia, retinitis pigmentosa, and Usher syndrome [10,12–15].”
Duarte, F. T., & Arsenijévic, Y. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101424 · Cited by 2
Fehrman, R. L., & Lipinski, D. M. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.11.38 · Cited by 2
Sarma, A. S., & Sharon, D. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101443 · Cited by 2
Goddaer, S., Coster, E. D., Callens, E., Caenegem, E. V., den Heule, O. V., Collin, R. W. J., Peynshaert, K., Nieuwerburgh, F. V., Braeckmans, K., & Remaut, K. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-02036-y · Cited by 2
“Trapani, et al. [15] demonstrated the feasibility of this concept in murine models by delivering oversized cDNAs such as MYO7A and ABCA4 via dual-AAV constructs, resulting in partial restoration of gene function.”
Boye, S. L., Durham, T. A., Laster, A., Gelfman, C. M., & Sahel, J. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.2.2 · Cited by 2
Outcomes of genetic testing for Usher syndrome in a diverse population cohort from South Florida
Cromar, Z. J., Chen, R. R., Riesgo, T. J., Yan, D. L. S., Verma, L. D., Chen, Z., Blanton, S. H., Lam, B. L., & Liu, X. Z. (2025) · Human Genomics · doi:10.1186/s40246-025-00775-0 · Cited by 2
“Several clinical trials are also underway investigating the use of antioxidant and targeted gene therapies for the slowing of USH progression [5, 6].”
Virus Vectors for Optogenetic Prosthetization of the Retina
Rotov, A. Y., Nikolaeva, D. A., Astakhova, L. A., & Firsov, M. L. (2020) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-020-00911-4 · Cited by 2
Stargardt Disease: Gene Therapy Strategies for ABCA4
Ku, C. A., & Yang, P. G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000375 · Cited by 2
Schizophrenia-like phenotypes and long-term synaptic plasticity impairment in GluN2A-transgenic mice
Zhang, H., Si, W., Wang, B., Han, J., Ding, F., Xue, Q., & Cao, X. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174026 · Cited by 1
The development of inner ear gene therapy for DFNB9: From bench to bedside
Drummond, M. C., & Chien, W. W. (2026) · Hearing Research · doi:10.1016/j.heares.2026.109590 · Cited by 1
Stargardt disease: progress, enigmas, and prospects for therapeutic intervention
Palmgren, V. A. C., Pindwarawala, M., Hosseinzadeh, A., & Molday, R. S. (2026) · Expert Review of Ophthalmology · doi:10.1080/17469899.2026.2645188 · Cited by 1
Punzo, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816222-4.00019-8 · Cited by 1
Recent Developments in Maculopathy
Bandello, F. M., Battista, M., Brambati, M., Starace, V., Arrigo, A., & Parodi, M. B. (2019) · Springer eBooks · doi:10.1007/978-3-030-25389-9_6 · Cited by 1
Emerging Treatments for Leber's Hereditary Optic Neuropathy and Other Genetic Causes of Visual Loss
Bakaeva, T. V., Mallery, R. M., & Prasad, S. (2019) · Seminars in Neurology · doi:10.1055/s-0039-3399504 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_150-1 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_150 · Cited by 1
(2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2014.2511 · Cited by 1
Emerging Therapies in Retinal Diseases: From Gene Therapy to Stem Cell Interventions
Gadre, P. P. G. A., Patil, P., Shirke, D. B., Sarwate, R., & Kundap, R. (2023) · International Journal on Recent and Innovation Trends in Computing and Communication · doi:10.17762/ijritcc.v11i7.9421 · Cited by 1
Peek, J. L., Rosales, A., Qi, J., Feleke, L., Menshikh, A., Welch, R., Woodard, L. E., Asokan, A., & Wilson, M. H. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201736 · Cited by 1
Dooley, S. J. (2018) · ScholarlyCommons (University of Pennsylvania)
Molecular insights into PCARE-associated retinal disease
Serrano, J. C. C. (2018) · Radboud Repository (Radboud University) · Cited by 1
Gene Therapy and Surgery for Retinal Diseases
Jiang, D. J., Xu, C. L., & Tsang, S. H. (2018) · Wiley eBooks · doi:10.1002/9780470015902.a0027221
Gene Therapy for Retinal Disease
McClements, M. E., & MacLaren, R. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00011-7 · Cited by 1
Benefits and Shortcomings of Laboratory Model Systems in the Development of Genetic Therapies
Bucher, K., Rodríguez‐Bocanegra, E., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1757-9879
“They are required for transgene expression assays that are performed to evaluate qualitative and quantitative transgene expression [10] and for biological activity or potency assays that serve to quantitatively measure the biological activity of the transgene [11].”
BackgroundInduced Pluripotency: Current Reprogramming Methods and Areas for Improved Therapeutic CapabilitiesPreprint
Lu, B., & Horowitz, N. B. (2023) · doi:10.14293/pr2199.000455.v1
Transient CRISPR-Cas delivery for therapeutic gene editing in the retina
Botto, C. (2022) · theses.fr (ABES) · doi:10.70675/b0c6037fz0240z4844z9036z7867f920dadc
Leclerc, D. (2023) · theses.fr (ABES) · doi:10.70675/265eb7f7zf02bz4293z9d8dz266599d45d4a
de Guimarães, T. A. C., & Michaelides, M. (2024) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-99-4436-1_16
“Seeing Stars”: The Gene Therapy Revolution
Mercer, G., Ballios, B. G., & Kertes, P. J. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-72230-1_59
Breaking the Silence, Lighting the Dark: Innovations in Usher Syndrome TreatmentPreprint
Singu, D., & Ho, L. (2025) · doi:10.58445/rars.3261
Usher Syndrome: Ocular Genetic Studies
UYGUR, D. İ., & Özmen, S. (2025) · Güncel Retina Dergisi (Current Retina Journal) · doi:10.37783/crj-0521
Rostamitehrani, Z., Javed, R., & Popplewell, L. J. (2025) · Muscles · doi:10.3390/muscles4040052
“As a result, a novel approach for the delivery of Sp Cas9 using dual hybrid AAV vectors has been developed [175].”
Ein Durchbruch für taub geborene Kinder: Erste erfolgreiche Gentherapie für Gehörlosigkeit
Reisinger, E. (2024) · German Medical Science (German Research Foundation) · doi:10.3205/zaud000046
Huang, D. (2021) · Murdoch University Research Portal
RESTORING AUDITORY FUNCTION IN MAMMALS USING AAV-BASED GENE THERAPY
Amariutei, A.-E. (2023) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Toualbi, L. (2024) · UCL Discovery (University College London)
Long, Y., Jia, Q., Zhang, W., Qin, H., & Yao, K. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5723
Владимирович, М. А., Анатольевна, С. С., Nikitin, S., Adyan, T., Akhkiamova, M., Borovikov, A. O., Buharova, T., Efimova, I. E., Zharkov, P., Kadyshev, V. V., et al. (2026) · doi:10.29039/978-5-94472-329-1-02-2026
Développement d’approches thérapeutiques pour le traitement des dysferlinopathies.
Pryadkina, M. (2014) · theses.fr (ABES) · doi:10.70675/27b540eaz8392z44b7zbfb0zbc47b0821d32
Ameline, B. (2016) · theses.fr (ABES) · doi:10.70675/7e510195z896bz4be6za7d5z616677c5bfa2 · Cited by 2
Neuillé, M. (2016) · theses.fr (ABES) · doi:10.70675/d55545d7ze4aaz43cfzbed2za2c6147a1901 · Cited by 1
Evolution dirigée de virus adéno-associés pour un transfert de gène efficace dans le système visuel
Planul, A. (2017) · theses.fr (ABES) · doi:10.70675/c9b178a1z8ba4z4451za409z4e80a603376f · Cited by 1
Towards Trans-Splicing Gene Therapy for HD : Intronic Targets Identification in the Huntingtin Gene
Maire, S. (2018) · theses.fr (ABES) · doi:10.70675/7910919eza0a5z4730z814bz3b4613350c43
Développement d'un traitement de thérapie génique pour la glycogénose de type III
Vidal, P. (2018) · theses.fr (ABES) · doi:10.70675/5e174471z66d8z44dbza2edz3adc480b1f41
Development of safe and efficient aav vectors for retinal gene therapy
Khabou, H. (2018) · theses.fr (ABES) · doi:10.70675/aa896663z9772z4d87z9bd1z247af1f0e3f1
Varin, J. (2020) · theses.fr (ABES) · doi:10.70675/f838cd61z108az4e28z9344z0b8ab2eae6bf · Cited by 2
Goyal, S., & Vanita, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43986-5.00042-4
Computational Rational Design of Larger AAV Icosahedral CapsidsPreprint
Cioffi, M., & Luque, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.09.724008 · Cited by 1
Kwon, J., Kim, Y. J., Kim, S.-H., Kwon, O.-S., Jang, H., Choi, Y., Na, H.-J., Han, N., Chun, Y., Han, J. H., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102971
“This added capacity may facilitate the design of dual-AAV or trans -splicing approaches for large retinal disease genes such as CEP290 ( ∼ 8.0 kb) 52 or ABCA4 ( ∼ 6.8 kb), 53 as well as emerging multi-component genome-editing platforms.”
InfluentialUpdate on the Management of ABCA4 Retinopathy (Stargardt Disease)
Parameswarappa, D. C., Ratra, D., Chattannavar, G., & Padhy, S. K. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01407-z
“The dual-vector concept evolved through three methods: overlapping regions, trans-splicing approaches, and hybrid dual-vector strategies [47, 51–54].”
Yin, L. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016169
Oloruntimehin, E. S., & Malogolovkin, A. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135668
“Experimental data have shown the efficiency of this approach in delivering large transgenes in inherited retinal diseases [187–191] and muscle [192].”
Gene Supplementation of MYO7A or activation of Myo7b for treatment of Usher syndrome 1BPreprint
Mittas, D. M., Otify, D. Y., Gavrilov, Z., Heigl, T., Suchomski, J., Deltuvaite, P., Hinrichsmeyer, K. S., Mercey, O., Kynast, F., Motlík, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.02.736025
Zhao, J., Xun, M., & Sun, Y. (2026) · Clinical and Translational Discovery · doi:10.1002/ctd2.70203
Esposito, F., Padmanabhan, A., Rhiel, M., Lupo, M., Marrocco, E., Auricchio, S., Cundin, X. B., Pellecchia, S., Cornu, T. I., Andrieux, G., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103047
Self-citationAn intersectional expression platform for gene complementation using RNA-fragment end joining (REJ)Preprint
Bachmann, L. C., Hsu, R. H., Hermann, K. J., Williams, C. E., Farman, R. L., Criales, N., Clark, C., Kramer, S., Pérez, C. T., Randles, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.13.751279
Antioxidant Strategies for Inherited Retinal Degenerations in the Era of Gene Therapy
Yang, Y., Chen, Q., Zeng, J., Liang, L., Tao, Z., She, K., Ren, C., & Lu, F. (2026) · Antioxidants · doi:10.3390/antiox15101229
“In addition, achieving sufficient co-transduction with multiple vector components may require greater overall vector exposure [51,54], potentially increasing dose-related AAV immune and inflammatory responses [55].”
Retinitis Pigmentosa: A Review of Its Pathogenesis and Emerging Molecular and Cellular Therapies
Tuli, N., Baeshen, M., Echbicheb, M., Kulbay, M., Ayalon, A., Ali, S. K., & Qian, C. X. (2026) · Vision · doi:10.3390/vision10040083
“However, this approach requires efficient cotransduction and transgene reconstitution, limiting its efficacy [82,83].”
Ocular Gene Therapy in China: Technological Framework, Clinical Translation, and Future Perspectives
Zhang, D., He, Z., Lu, F., & Yang, Y. (2026) · Human Gene Therapy · doi:10.1177/10430342261495300
Du, J., Meng, X., Fan, P., & Si, N. (2026) · Genes · doi:10.3390/genes17111321
Metadata
- Authors
- Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., Farrar, G. J., Polishchuk, R., & Auricchio, A.
- Affiliations
- Telethon Institute Of Genetics And Medicine (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- University of Bologna (IT)
- Trinity College Dublin (IE)
- Federico II University Hospital (IT)
- Corresponding author
- Auricchio, Alberto
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2013-12-16
- Volume
- 6
- Issue
- 2
- Pages
- 194-211
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC3927955
- OpenAlex
- W2137826201
- Cited by
- 269
- References
- 82
- Citations by year
- 2026: 18 · 2025: 30 · 2024: 17 · 2023: 24 · 2022: 18 · 2021: 24 · 2020: 31 · 2019: 22 · 2018: 22 · 2017: 23 · 2016: 9 · 2015: 17 · 2014: 13 · 2013: 1
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/3.0/ (tdm)
- creativecommons.org/licenses/by/3.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- European Research Council/ERC (282085)
- European Community's Seventh Framework Programme (242013)
- NIH (R24 RY019861‐01A)
- Italian Telethon Foundation (TGM11MT1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, retinal gene therapy, trans-splicing, homologous recombination, hybrid vectors, Stargardt disease, photoreceptors, inherited retinal disease
- MeSH terms
- Stargardt Disease, Myosin VIIa, Dependovirus, Animals, Disease Models, Animal, Genetic Vectors, Humans, Injections, Lipofuscin, Macular Degeneration, Mice, Inbred C57BL, Myosins, Phenotype, Retina, Rhodopsin, Transduction, Genetic, Gene Transfer Techniques, ATP-Binding Cassette Transporters, Trans-Splicing, Photoreceptor Cells, Vertebrate, Melanosomes, Sus scrofa, Mice, Usher Syndromes, Retinal Pigment Epithelium, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.